Cargando…
Corrigendum to “Beneficial immune-modulatory effects of the N-163 strain of Aureobasidium pullulans-produced 1,3-1,6 Beta glucans in Duchenne muscular dystrophy: Results of an open-label, prospective, exploratory case-control clinical study” [IBRO Neurosci. Rep. 15 (2023), pp. 90–99]
Autores principales: | Raghavan, Kadalraja, Dedeepiya, Vidyasagar Devaprasad, Srinivasan, Subramaniam, Pushkala, Subramanian, Bharatidasan, Sudhakar S., Ikewaki, Nobunao, Iwasaki, Masaru, Senthilkumar, Rajappa, Preethy, Senthilkumar, Abraham, Samuel J.K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428020/ https://www.ncbi.nlm.nih.gov/pubmed/37593322 http://dx.doi.org/10.1016/j.ibneur.2023.08.001 |
Ejemplares similares
-
Beneficial immune-modulatory effects of the N-163 strain of Aureobasidium pullulans-produced 1,3-1,6 Beta glucans in Duchenne muscular dystrophy: Results of an open-label, prospective, exploratory case-control clinical study
por: Raghavan, Kadalraja, et al.
Publicado: (2023) -
Beneficial effects of novel aureobasidium pullulans strains produced beta-1,3-1,6 glucans on interleukin-6 and D-dimer levels in COVID-19 patients; results of a randomized multiple-arm pilot clinical study
por: Raghavan, Kadalraja, et al.
Publicado: (2022) -
Hepatoprotective Effects of Aureobasidium pullulans Derived β 1,3–1,6 Glucans in a Murine Model of Non-alcoholic Steatohepatitis
por: Ikewaki, Nobunao, et al.
Publicado: (2022) -
Improvement of behavioural pattern and alpha-synuclein levels in autism spectrum disorder after consumption of a beta-glucan food supplement in a randomised, parallel-group pilot clinical study
por: Raghavan, Kadalraja, et al.
Publicado: (2022) -
Integrating the Synergy of the Gut Microbiome into Regenerative Medicine: Relevance to Neurological Disorders
por: Preethy, Senthilkumar, et al.
Publicado: (2022)